trending Market Intelligence /marketintelligence/en/news-insights/trending/bqRlJ-nhKB2SWpGGhYoNYA2 content esgSubNav
In This List

Merck's Keytruda approved as 1st-line treatment of lung cancer in Japan

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Merck's Keytruda approved as 1st-line treatment of lung cancer in Japan

Japan's Ministry of Health, Labour, and Welfare approved Merck & Co. Inc.'s Keytruda as first- and- second-line treatment of patients with certain types of advanced or recurrent non-small cell lung cancer.

The drug will be manufactured within the country and promoted with Taiho Pharmaceutical Co. Ltd., Merck said.

The drug was also recommended by the European Medicines Agency's Committee for Medicinal Products for Human Use as first-line treatment of metastatic non-small cell lung cancer in adults. Keytruda is already approved for use in melanoma, lung, head and neck cancer in the U.S.